Primary biliary cholangitis: personalized medicine for optimal therapeutic opportunities

作     者：Yulong Shang Patrick S.C.Leung M.Eric Gershwin Ying Han 尚玉龙;Patrick S.C.Leung;M.Eric Gershwin;韩英

作者机构：National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive DiseasesXijing HospitalAir Force Military Medical UniversityXi’an 710032China Division of RheumatologyAllergy and Clinical ImmunologyUniversity of CaliforniaDavis 95616USA 

出 版 物：《Science Bulletin》 (科学通报（英文版）)

年 卷 期：2022年第67卷第24期

页      面：2498-2501页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China(81820108005 and 81900502) the National Key Research and Development Program of China(2017YFA0105704) Key Research and Development Program of Shaanxi(2021ZDLSF02-07) 

主　　题：diagnosis inflammation Primary 

摘      要：Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease that is characterized by inflammation of the interlobular bile ducts. Although PBC is a slowly progressive disease, with a natural history of 10–15 years leading to end-stage liver disease, highrisk cases may rapidly progress to decompensated cirrhosis or even death. As the most common autoimmune liver disease, the prevalence of PBC has been increasing globally, largely due to increased disease awareness, improved diagnosis, and treatment with ursodeoxycholic acid (UDCA). PBC is more likely to occur in middle-aged women, with a female-to-male ratio ranging from 1.6 to10;however, men have a higher disease severity [1,2].